Review
Nature Reviews Cancer 7, 585-598 (August 2007) | doi:10.1038/nrc2189
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Teru Hideshima1, Constantine Mitsiades1, Giovanni Tonon1, Paul G. Richardson1 & Kenneth C. Anderson1 About the authors
Abstract
Multiple myeloma is a plasma cell malignancy characterized by complex heterogeneous cytogenetic abnormalities. The bone marrow microenvironment promotes multiple myeloma cell growth and resistance to conventional therapies. Although multiple myeloma remains incurable, novel targeted agents, used alone or in combination, have shown great promise to overcome conventional drug resistance and improve patient outcome. Recent oncogenomic studies have further advanced our understanding of the molecular pathogenesis of multiple myeloma, providing the framework for new prognostic classification and identifying new therapeutic targets.
- View At a Glance
Author affiliations
- Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA.
Correspondence to: Kenneth C. Anderson1 Email: kenneth_anderson@dfci.harvard.edu
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Combined therapeutic strategy using erythropoietin and mesenchymal stem cells potentiates neurogenesis after transient focal cerebral ischemia in ratsJournal of Cerebral Blood Flow & Metabolism Original Article
Inflammatory cell infiltration after endothelin-1-induced cerebral ischemia: histochemical and myeloperoxidase correlation with temporal changes in brain injuryJournal of Cerebral Blood Flow & Metabolism Original Article
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myelomaLeukemia Original Article
See all 14 matches for Research